Concepedia

Robert L. Shepard

RL

Statistics

Publications

28

Citations

2.5K

H-Index

25

Active since

1973

Affiliations

Eli Lilly (United States)(Current)

Queen's University

St. Jude Children's Research Hospital

Vanderbilt University

Millennium Engineering and Integration (United States)

Robert L. Shepard is an author at Eli Lilly (United States) specializing in pharmacology, medicine, and molecular pharmacology.

ORCID

Publications per year

1973–2017

28

Publications

28

Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979.

Anne H. Dantzig, Robert L. Shepard, Jin Cao et al. · PubMed · 1996 · 328 citations

, , +17

The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites

Susan E. Pratt, Robert L. Shepard, Ramani A. Kandasamy et al. · Molecular Cancer Therapeutics · 2005 · 261 citations

, , +17

Application of Three-Dimensional Quantitative Structure-Activity Relationships of P-Glycoprotein Inhibitors and Substrates

Sean Ekins, Richard B. Kim, Brenda F. Leake et al. · Molecular Pharmacology · 2002 · 185 citations

, , +17

Association of Intestinal Peptide Transport with a Protein Related to the Cadherin Superfamily

Anne H. Dantzig, JoAnn Hoskins, Linda B. Tabas et al. · Science · 1994 · 181 citations

, , +16

Selectivity of the Multidrug Resistance Modulator, LY335979, for P-Glycoprotein and Effect on Cytochrome P-450 Activities

Anne H. Dantzig, Robert L. Shepard, K L Law et al. · Journal of Pharmacology and Experimental Therapeutics · 1999 · 179 citations · Full text

, , +17

1–5 of 28